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Abstract
Introduction Two recent studies have shown that
modern bariatric surgery leads to significant hyper-
oxaluria and risk of nephrolithiasis. However, neither
report evaluates the use or effects of stone risk
modifying agents in these patients. We sought to
determine the impact of medical management on
stone risk profile in patients who have undergone
Roux-en-y gastric bypass.
Materials and methods Twenty-four-hour urine
collections of all patients referred to a tertiary clinic
for nephrolithiasis in the past 4 years were reviewed.
Those patients with severe ([75 mg/day) hyperoxal-
uria were identified. Retrospective chart review was
performed to identify those patients with a history of
bariatric surgery. Student’s t-test was used to com-
pare mean urinary parameters between bariatric and
non-bariatric patients.
Results Out of all stone formers within our 24-h
urine collection database, 39 patients had severe
hyperoxaluria (oxalate [75 mg/day). Twenty-six
patients had complete information for review. Five
patients had a history of bariatric surgery. Compared
with non-bariatric patients, those with a history of
bariatric surgery had increased use of oral calcium
(80 vs. 28%) and citrate supplementation (100 vs.
47%), higher urinary oxalate (129 vs. 91 mg/day) and
volume (2.9 vs. 2.4 L/day), lower urinary citrate (390
vs. 800 mg/day) and calcium (155 vs. 235 mg/day),
and a decreased supersaturation of calcium oxalate
(6.7 vs. 11).
Conclusions Appropriate medical management, in
particular oral calcium and citrate supplementation,
and perhaps most importantly aggressive fluid intake
can mitigate some of the effects of enteric hyperox-
aluria caused by fat malabsorption after modern
bariatric surgery.
Keywords Obesity  Bariatric surgery 
Urinary calculi  Calcium oxalate
Introduction
Obesity is an increasingly prevalent problem in the
United States [1]. Seventeen percent of children and
32% of adults in the US meet the clinical definition of
obesity. In adult men and in adolescents of both sexes,
these numbers have been climbing over the past
6 years, and in women the rate of obesity seems to be
leveling off. The obesity epidemic has been related to
sedentary lifestyle, increased use of processed or high
caloric foods, and other trends. A prospective study of
three large cohorts found that compared to matched
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controls, obese patients were 1.44 (men) and 1.92
(women) times as likely to form stones [2]. Other
studies have shown that obese patients have an
increased excretion of stone-promoting substances
[3].
The newest trend in treatment of morbid obesity is
Roux-en-y gastric bypass or gastric banding. The rate
at which these procedures are being performed has
increased 600% from 1996 to 2001 [4]. In the 1970s,
jejunoileal bypass led to significant complications,
including nephrolithiasis, ranging from 11% at 1 to
5 years [5] to as high as 39% after 15 years [6]. In
contrast, modern bariatric surgery procedures, which
are touted to cause less malabsorption than jejuno-
ileal bypass, have been postulated to have less impact
on urinary stone risk.
Yet kidney stones were recently found to be one of
the top 10 postoperative diagnoses in modern bari-
atric patients [7]. A separate retrospective study
found de novo stone formation in 3.2% of patients;
however, for patients with a history of nephrolithi-
asis, 31.4% were found to have recurrent stones after
bypass surgery [8]. In addition, hyperoxaluria was
recently confirmed to be the most significant abnor-
mality in urinary stone risk profile after modern
bariatric surgery [9]. Furthermore, hyperoxaluria has
been shown to increase as time from surgery
increases [10]. In both of these studies, the patients
had low urinary volumes, and in neither study did the
authors comment on the use of oral medications to
modify stone risk.
Given what has been described as a pending
epidemic in nephrolithiasis in patients undergoing
modern bariatric surgery, [11] we sought to evaluate
the effects of medical management on urinary
biochemical data between hyperoxaluric patients
with and without a history of bariatric surgery.
Materials and methods
A retrospective study of urine chemistries was
performed. Patients selected for the study had been
referred to a urinary stone practice at a tertiary
medical center for at least one episode of urolithiasis;
many patients had previously undergone 24-h urine
collection and/or been placed on some form of
medical therapy by the referring urologist. Included
patients had submitted at least two outpatient 24-h
urine collections (within *1 week’s time) and a
questionnaire to a commercial laboratory (Litholink,
Chicago, Ill). As in many practices, we recommend to
all of our stone patients to decrease sodium, limit
animal protein, and drink sufficient fluids so as to
maintain a urine volume around 2 L/day. We also use
the 24-h urine collection to make specific recom-
mendations for dietary change and medical therapy.
However, given the known tendency to chronic
acidemia, hypocitraturia, and enteric hyperoxaluria
in patients who have undergone bariatric surgery, we
place all of these patients on 1,200 mg oral calcium
divided up with meals as well as 20 meq potassium
citrate three times daily.
Those patients with severe ([75 mg/day) hyper-
oxaluria were identified. Retrospective chart review
was performed to determine their medical and surgi-
cal histories, especially regarding intestinal surgery
and use of medications. An average value (over the
two samples submitted by each patient) was deter-
mined for each urinary stone risk factor. Urinary pH
was measured using a pH electrode. Calcium, mag-
nesium, uric acid, creatinine, phosphorous, sodium,
potassium, and ammonium were measured using a
Beckman autoanalyzer (Beckman Instruments, Brea,
CA). Urine supersaturations of calcium oxalate,
calcium phosphate, and uric acid were calculated by
the iterative computer program, Equil II [12]. In
addition, the patient’s self-reported information on 19
clinical parameters was included—including family
history, personal stone history, and use of stone risk
modifying medications. Comparison between groups
was made using the Student’s t-test utilizing com-
mercially available statistical analysis software
(SPSS, Chicago, IL).
Results
We identified 39 patients who had severe hyperoxal-
uria (oxalate [75 mg/day), 26 of whom had clinic
charts available for review of medical and surgical
histories. Five of these 26 patients were found to have
a history of Roux-en-y gastric bypass surgery. No
bariatric surgery patient reported a history of nephro-
lithiasis prior to weight reduction surgery. In addition,
none of the operations had taken place within the year
prior to 24-h urine collection. A single non-bariatric
patient had documented Crohn’s disease and was
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excluded. All included non-bariatric patients had
presumed dietary or idiopathic hyperoxaluria.
The mean age, weight, and medication use are
shown in Table 1. Patient age ranged from 42 to
73 years. Seventy-six percent of the non-bariatric
patients were men, although 80% of the bariatric
patients were female. Bariatric patients were heavier
than non-bariatric patients (97 vs. 78 kg). Non-
bariatric and bariatric patients had a similar number
of lifetime stone episodes (4.1 vs. 3.6). Oral calcium
supplement (80 vs. 28%) and potassium citrate (100
vs. 47%) use were more common in the bariatric than
non-bariatric patients.
Tables 2, 3, and 4 provide a summary of the urinary
biochemical data. Those patients with a history of
bariatric surgery had a significantly higher chloride
(350 vs. 190 P \ 0.01), a lower citrate (390 vs. 800
P = 0.04), higher oxalate (130 vs. 91 P \ 0.01), and
higher sodium (350 vs. 210 P \ 0.01). Urinary volume
was 500 mL greater in the bariatric than non-bariatric
group (2.9 vs. 2.4 L P = 0.36).
The concentration of each urinary solute also was
calculated and compared between the two groups. The
supersaturation of different stone constituents is
determined more by solute concentration, rather than
net amount excreted per day. These results can be
found in Table 3. Only chloride (120 vs. 85 P = 0.04)
and citrate (130 vs. 390 P = 0.05) showed a statis-
tically significant difference. Calcium concentration
was almost 50% less in bariatric patients versus non-
bariatric patients, although this did not reach statis-
tical significance (54 vs. 99 P = 0.13).
No difference was seen in the supersaturation of
uric acid or calcium phosphate. The supersaturation
of calcium oxalate was 40% less in the bariatric
patients versus the non-bariatric patients with hyper-
oxaluria (6.7 vs. 11 P = 0.13). These results can be
found in Table 4.
Table 1 Characteristics of hyperoxaluric patients
Non-bariatric (n = 21) Bariatric (n = 5)
Mean age (years) 54 54
Males (%) 76 20
Weight (kg) 78 97
Hctz (%) 19 20
Calcium supp. (%) 29 100
Citrate supp. (%) 48 60
Allopurinol (%) 10 0
Table 2 Mean 24-h urine parameters by history of bariatric
surgery
Non-bariatric Bariatric P-value
Ammonium 41 58 0.17
Calcium 240 160 0.25
Chloride 190 350 0.01
Citrate 800 390 0.04
Creatinine 1,900 1,600 0.36
Magnesium 130 130 0.88
Oxalate 91 130 0.01
pH 6.3 6.1 0.58
Phosphorous 1.2 1.2 0.75
Potassium 93 100 0.71
Sodium 210 350 0.01
Sulfate 51 58 0.60
Urea nitrogen 14 13 0.77
Uric acid 0.89 0.76 0.34
Volume 2.5 2.9 0.39
Table 3 Mean 24-h urine concentrations by history of bari-
atric surgery
Non-bariatric Bariatric P-value
Ammonium 19 21 0.69
Calcium 99 54 0.13
Chloride 85 120 0.04
Citrate 390 130 0.05
Creatinine 860 590 0.11
Magnesium 57 49 0.48
Oxalate 41 47 0.48
Phosphorous 0.54 0.42 0.38
Potassium 42 34 0.48
Sodium 91 120 0.08
Sulfate 23 19 0.57
Urea nitrogen 6.3 4.8 0.32
Uric acid 0.41 0.27 0.10
Table 4 Mean 24-h urine supersaturations by history of ba-
riatric surgery
Non-bariatric Bariatric P-value
SS UA 0.82 0.67 0.76
SS CaOx 11 6.7 0.13
SS CaPhos 1.4 0.64 0.25
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Discussion
Oxalate excretion has been identified as a major risk
factor for stone formation for decades. Hyperoxaluria
following bariatric surgery was definitively shown to
be from increased intestinal oxalate absorption in the
early 1980s [13]. In this study, six patients were
placed on an oxalate diet, a low-oxalate diet, and total
parenteral nutrition. Urinary oxalate on a low-oxalate
diet decreased by half, while on total parenteral
nutrition, a fourfold decrease in urinary oxalate was
found. A complementary study revealed the impor-
tance of high oral calcium intake in binding luminal
oxalate. The average urinary oxalate doubled when
dietary calcium was reduced from 3,000 to 250 mg/
day [14]. These studies clearly show that dietary or
medical intervention can mitigate some of the effects
of bariatric surgery. In an attempt to further define the
effects of aggressive medical management on urinary
stone risk profile in patients undergoing Roux-en-y
gastric bypass, we retrospectively identified and
compared hyperoxalurics with and without a history
of bariatric surgery.
The most notable finding of this study was that
following bariatric surgery, patients had a surprisingly
low supersaturation of calcium oxalate of 6.7. This was
mainly due to a significantly lower urinary calcium
concentration. In fact, the supersaturation of calcium
oxalate in our bariatric patients is similar to that found
in a previous large cohort study of normal, overweight,
and obese stone formers. The obese stone formers had
a supersaturation of calcium oxalate (by the EQUIL
equation) of 6.14 (men) and 5.97 (women) [15].
Therefore, by comparison, our obese patients after
bariatric surgery had a supersaturation of calcium
oxalate, which was only 10% higher. This finding is in
contradiction to a study in the early 1980s that looked
at 24-h urine collections in obese patients before and
both 2 and 5 years after jejunoileal bypass surgery.
Following surgery, urinary calcium decreased from
baseline, and oxalate excretion was threefold higher,
despite calcium supplementation. However, in this
study, the relative SS product (by Robertson’s equa-
tion) increased by a full 40% following surgery [16].
However, the low supersaturation of calcium
oxalate in our bariatric patients with hyperoxaluria
is even more surprising given recent data published by
Asplin [9]. This found a SS CaOx in gastric bypass
and jejunoileal bypass patients that was nearly twice
as high as our value of 6.7. Although our patients had
higher urinary oxalate (130 vs. 100 mg/day), higher
urinary calcium (160 vs. 140 mg/day), and lower
citrate (390 vs.*400 mg/day), our patients’ urinary
volume was significantly greater (2.9 vs. 1.8 L). This
may be the key difference between our bariatric stone
formers and those of Asplin. Thus, many of the
recommendations that are applicable to the stone-
forming public in general, i.e., increased fluid intake,
can have a significant impact on stone-forming risk
even in this highly selected population.
Similarly, citrate has been studied extensively in
weight reduction surgery patients. Citrate is a known
inhibitor of the formation of calcium oxalate stones.
Bariatric surgery can have profound effects on urinary
citrate levels due to chronic metabolic acidosis. A
study in jejunoileal bypass patients found a mean
urinary citrate of 22 mg/day. These patients subse-
quently underwent bypass reversal with an increase in
urinary citrate to 230 mg/day. Citrate supplementa-
tion was initiated, and urinary levels rose further to
550 mg/day [17]. In contrast, we did not see a
significant degree of hypocitraturia in our studied
bypass patients. This was likely influenced by the fact
that all of the bariatric surgery patients were taking
potassium citrate at the time of 24-h urine collection.
However, urinary citrate levels were still significantly
lower in the bariatric patients than non-bariatric
patients, despite their higher rate of citrate supple-
mentation. Additionally, compliance is supported by
the mean urinary potassium level (100 mg/day) since
for every one mEq of potassium intake; approximately
one mEq of potassium appears in the urine.
The influence of inhibitors of urinary stone forma-
tion also has been studied in weight reduction surgery
patients. High oxalate levels in the intestine bind not
only calcium, but also magnesium (a stone inhibitor).
High calcium oxalate stone indices following jejuno-
ileal bypass have been attributed to both to high
urinary oxalate and low urinary magnesium [18], and
80% of our bariatric patients were on oral calcium,
which likely lowered both oxalate absorption and
oxalate available for magnesium binding. Therefore,
it is not surprising that our study found no difference
in magnesium levels between hyperoxaluric patients
with or without a history of bariatric surgery.
Our study included a large number of patients with
hyperoxaluria, but was limited by its retrospective
nature and small size of specific patients with a
372 Int Urol Nephrol (2010) 42:369–374
123
history of bariatric surgery. Since most patients were
seen after evaluation and treatment by an outside
urologist, we were not able to examine an individual
patient’s response to any given therapy, i.e., a change
in 24-h urine over time. Furthermore, although we
were able to determine from chart review that all of
the bypass procedures had taken place over a year
prior to 24-h urine collection, the exact dates of
surgery could not be determined. Additionally, the
comparison groups differed in distribution of gender,
as more of the bariatric patients were women. Men in
general have higher urine SS CaOx, which could
have brought the results closer to the null hypothesis.
While it is reassuring that none of our bariatric
patients had renal insufficiency to suggest oxalate
nephropathy, a recent study reported on two patients
(8.7% of the study cohort) with renal failure
presumed to be due to hyperoxaluria after Roux-en-
y gastric bypass [19].
Future studies could focus on 24-h urine collec-
tions in patients before and after bariatric surgery.
This kind of internal control could factor in each
patient’s inherent stone-forming risk, with the addi-
tional risks of obesity and subsequent bariatric
surgery and weight loss. This could be performed in
a prospective fashion in coordination with a bariatric
surgery center. These patients undergo extensive
evaluations with sometimes multiple follow-up visits
prior to surgery, and the opportunity likely exists for
enrollment in a clinical trial. Because of the dramatic
increase in the numbers of these procedures, as well
as the potential difficulties in performing stone
operations in these patients, we need to know
significantly more about the exact risk and nature of
stone formation in these patients.
Conclusions
Despite the anticipated significantly higher oxalate
levels, compared with other hyperoxaluric patients,
modern bariatric surgery patients had a dramatically
lower supersaturation of calcium oxalate, predomi-
nantly due to higher urinary volume and lower
urinary calcium excretion. Appropriate medical man-
agement, in particular oral calcium supplementation
and aggressive fluid intake may mitigate some of the
effects of enteric hyperoxaluria after modern bariatric
surgery.
Open Access This article is distributed under the terms of the
Creative Commons Attribution Noncommercial License which
permits any noncommercial use, distribution, and reproduction
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